Kavmyl 600 mg. 50 mg. 300 mg Film-coated tablets
PDF Leaflet Revision Date: 03 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV infection in adults and adolescents.
Dosage (summary)
One tablet once daily for adults and adolescents >40 kg.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; potential risk of neural tube defects.
Key Drug Interactions
- Metformin (contraindicated)
- Dofetilide (contraindicated)
- Carbamazepine (not recommended)
Contraindications
- Hypersensitivity to abacavir, dolutegravir, or lamivudine
- Moderate to severe hepatic impairment
- Creatinine clearance <50 mL/min
Common side effects
- Hypersensitivity reactions
- Nausea
- Fatigue
- Insomnia
- Headache
Counselling Points
- Screen for HLA-B*5701 allele before starting therapy.
- Report any signs of hypersensitivity immediately.
- Do not restart KAVMYL after hypersensitivity reaction.
Serious warnings
- Risk of life-threatening hypersensitivity reactions
- Lactic acidosis
- Immune reconstitution inflammatory syndrome
Important Disclaimer
The Kavmyl 600 mg. 50 mg. 300 mg Film-coated tablets professional information leaflet below is the property of Viatris Healthcare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
